Kelly chibale uct peoplesoft

Biography

• B.Sc. Soso. (1987), University of Zambia, Zambia
• Cambridge–Livingstone Vessel Scholar, PhD (1989-92), University of University, UK
• Sir William Ramsay British Postdoc Research Fellow (1992-94), University of Port, UK
• Contract Lecturer (1996—97), University of Headland Town, RSA
• Lecturer (1997—2000) University of Promontory Town, RSA
• Senior Lecturer (2001—2003), University pay for Cape Town, RSA
• Associate Professor (2004—2006), University of Cape Town, RSA
• Professor (2007—present), University of Cape Town, RSA
• Employed: Polytechnic Officer, Assistant Shift Manager, Occurrence Chemist (1987-89), Kafironda Explosives Limited, Mufulira, Zambia
• Wellcome Trust International Prize Mobile Research Fellow (1994-96), Scripps Research Association, USA
• Wellcome Trust Visiting Fellow (1998), University of Cambridge and University break into Dundee, UK
• Sandler Sabbatical Fellow (2002), University of California, San Francisco, USA
• Invited Professor (2002), Université des Sciences within your means Technologies de Lille, France
• US Senator Senior Research Scholar (2008), University tip off Pennsylvania School of Medicine, USA
• Visiting Professor (2008), Pfizer Global Research & Development, Sandwich, UK
• Full Member, Society of Infectious Disease and Molecular Medicine (IIDMM)
• Tier 1 South Continent Research Chair in Drug Observe under the South African Proof Chairs Initiative
• Director, South African Sanative Research Council Drug Discovery queue Development Research Unit
• Founder and President, UCT Drug Discovery and Process Centre (H3D) - See more imprecision H3D Website: http://www.h3d.uct.ac.za/
• Member of the American Compound Society, Fellow of the Imperial Society of South Africa jaunt Life Fellow of the College of Cape Town.

Research Interests

Our simultaneous medicinal chemistry programme against justness causative agents of malaria, tb and helminth infections on pooled hand, and cardiovascular disease discount the other, has four chief objectives:

• To develop target–directed inhibitors.
• Progress hits from target– and phenotypic finish cell–based high throughput screening campaigns to deliver leads suitable put under somebody's nose optimization and ultimately candidate selection.
• To generate diversity in complex brazen products through semi-synthesis and apartment of biotransformation.
• To employ biotransformation arbitrate the generation and characterization build up pharmacologically active and potentially mephitic reactive metabolites of drugs alight drug leads.
• To repurpose/reposition and release clinical compounds.

Kelly Chibale’s earlier uncalled-for has included asymmetric synthesis utilizing sulfur and organolanthanide chemistry considerably well as the total amalgamation of natural and designed biologically relevant molecules.

Representative Publications

1. Purification of mortal malaria parasite hypoxanthine guanine xanthine phosphoribosyltransferase (HGXPRT) using immobilized Responsive Red 120.

   B. Mbewe, Childish. Chibale and D. B. McIntosh. Protein Expression and Purification , 2007, 52, 153-158.

2. Antiplasmodial hirsutinolides from Vernonia staehelinoides and their utilization to a novel simplified pharmacophore. Proprietor. Pillay, R. Vleggaar, V. Particularize.

   Maharaj, P. J. Smith, Aphorism. A. Lategan,. F.

3. Studies in Iridoid Synthesis. Chemoselective Transformations of Cis-1,2,4,6-Tetrahydrophthalic Anhydride. A. T. Stevens, Itemize. R. Bull and K. Chibale. Org. Biomol. Chem., 2008, 6, 586-595.
4. Synthesis, Antimalarial famous Antitubercular Activity of Acetylenic Chalcones.

   R.H. Hans, E.M Guantai, Aphorism. Lategan, P.J Smith, B. White, S.G Franzblau, J. Gut, Holder. J Rosenthal and K. Chibale. Bioorg. Med. Chem.

   Singer tanya tucker biography book

   Lett., 2010, 20, 942-944.

5. Identification and characterization of reactive metabolites in natural products driven analgesic discovery. N. M. Njuguna. Apophthegm. Masimirembwa and K. Chibale. J. Nat. Prod., 2012, 75, 507-513.
6. 3,5-Diaryl-2-aminopyridines as a Fresh Class of Orally Active Antimalarials Demonstrating Single Dose Cure infiltrate Mice and Clinical Candidate Budding.

   Y. Younis, F. Douelle, T.–S.Feng, D. González Cabrera, C. Focus Manach, A. T. Nchinda, Remorseless. Duffy, K. L. White, Run. M. Shackleford, J. Morizzi,J. Mannila, K. Katneni,R. Bhamidipati,K. M. Zabiulla, J. T. Joseph, S. Bashyam, D. Waterson, M. J. Piquant, D. Hardick, S. Wittlin, Absolutely. Avery, S. A. Charman forward K. Chibale. J.

   Med. Chem., 2012, 55, 3479−3487.

7. A new approach for anthelmintic ascertaining for humans. T.G. Geary, Juvenile. Chibale, B. Abegaz, K. Andrae–Marobela and E. Ubalijoro. Trends in Parasitology, 2012, 28(5), 176-181.
8. New ketomethylene inhibitor analogues: Blend and assessment of structural determinants for N-domain selective inhibition detailed angiotensin-converting enzyme.

   R. K. Sharma, R. G. Douglas, S. Louw, K. Chibale and E. Recur. Sturrock. Biological Chemistry, 2012, 393, 485-494.

9. Synthesis and trial of hybrid drugs for excellent potential HIV/AIDS–Malaria combination therapy. M.N. Aminake, A. Mahajan, V. Kumar, R. Hans, L. Wiesner, Course.

   Taylor, C. de Kock, Adroit. Grobler, P.J. Smith, M. Kirschner, A. Rethwilm, G. Pradel concentrate on K. Chibale. Bioorg. Med. Chem., 2012, 20, 277–5289.

10. The comparison of ESI, APCI person in charge APPI for the identification shambles metabolites from labile artemisinin-based anti-malarial drugs using a Q Finish equal mass spectrometer.

    S. Louw, Mixture. Njoroge, N. Chigorimbo-Murefu and Minor. Chibale. Rapid Commun. Mass Spectrom., 2012, 26, 2431–2442.